媒體教育 Anti-EGFR rechallenge in prior responders with metastatic colorectal cancer

Rechallenging prior responders to anti-epidermal growth factor receptor (EGFR) therapy with the same targeted agent upon disease progression is a relatively new approach in the management of metastatic colorectal cancer (mCRC). Dr. Siu-Hong Lee, Specialist in Clinical Oncology in Hong Kong, discussed the evidence supporting this approach in patients with RAS wild-type mCRC who responded previously to an anti-EGFR therapy such as cetuximab, as well as his initial experience with this treatment strategy.

Dr. Siu-Hong Lee